{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-022922","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.619636+00:00","generated_at":"2026-06-23T07:58:05.387907+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones","bullets":["Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.","Potential regulatory and commercial milestones up to $287.3 million, plus tiered royalties.","Puma responsible for development, manufacturing, and commercialization globally.","Must use commercially reasonable efforts in US, UK, France, Germany, Italy, Spain, and Japan.","Puma can terminate on 120 days' notice; Takeda may terminate if Puma halts activities for >12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-022922","json":"https://secwatch.observer/filing/0001437749-22-022922.json","markdown":"https://secwatch.observer/filing/0001437749-22-022922.md","text":"https://secwatch.observer/filing/0001437749-22-022922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/0001437749-22-022922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/pbyi20220922_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:58:05.387907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}